Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.87 |
| ▸ | TGM2 | P21980 | 1/20 | 0.78 |
| ▸ | KRAS | P01116 | 5/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.70 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.64 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.63 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941868 | 1.00 | NT5E (0.87) | NT5ETGM2KRASP2RX3ALDH1A1 | |
| SCHEMBL24409559 | 1.00 | NT5E (0.87) | NT5ETGM2KRASP2RX3ALDH1A1 | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL12714637 | 0.93 | NT5E (1.00) | NT5ETGM2KRAS | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL4312033 | 0.93 | NT5E (1.00) | NT5ETGM2KRAS | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL12714656 | 0.93 | NT5E (1.00) | NT5ETGM2KRAS | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL21067782 | 0.93 | NT5E (1.00) | NT5ETGM2KRAS | |
| SCHEMBL21067722 | 0.93 | TGM2 (0.85) | NT5ETGM2KRASP2RX3ALDH1A1 | |
| SCHEMBL29429843 | 0.93 | TGM2 (0.85) | NT5ETGM2KRASP2RX3ALDH1A1 | |
| SCHEMBL851357 | 0.93 | TGM2 (0.85) | NT5ETGM2KRASP2RX3ALDH1A1 | |
| SCHEMBL18769114 | 0.93 | TGM2 (0.85) | NT5ETGM2KRASP2RX3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584916-B2 | Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues | CISBIO BIOASSAYS (FR) | 2026-03-24 | — | — | US | claimed |
| US-12522656-B2 | Anti-G-protein alpha antibody | CISBIO BIOASSAYS (FR) | 2026-01-13 | — | — | US | claimed |
| US-12492234-B2 | Fiber assembly and use thereof | KYOTO UNIVERSITY (JP) | 2025-12-09 | — | — | US | claimed |
| EP-3658913-B1 | METHOD FOR MEASURING MODULATION IN THE ACTIVITY OF A G PROTEIN-COUPLED RECEPTOR | CISBIO BIOASSAYS (FR) | 2024-04-03 | — | — | EP | claimed |
| CN-111164427-B | Method for measuring modulation of G protein coupled receptor activity | CISBIO生物试验公司 | 2023-12-19 | — | — | CN | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023149801-A1 | METHOD FOR PREPARING A CONFORMATION-SPECIFIC ANTIBODY. | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-08-10 | — | — | WO | claimed |
| US-20230135945-A1 | Method for Measuring Modulation in the Activity of a G Protein-Coupled Receptor | CISBIO ASSAYS (FR) | 2023-05-04 | — | — | US | claimed |
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | CISBIO BIOASSAYS (FR) | 2023-03-23 | — | — | US | claimed |
| EP-4097133-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | CISBIO BIOASSAYS (FR) | 2022-12-07 | — | — | EP | claimed |
| CN-115397858-A | anti-G protein alpha antibody | CISBIO生物试验公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220099669-A1 | METHOD FOR MEASURING THE MODULATION OF THE ACTIVATION OF A G PROTEIN-COUPLED RECEPTOR WITH GTP ANALOGUES | CISBIO BIOASSAYS (FR) | 2022-03-31 | — | — | US | claimed |
| US-20260132178-A1 | ENGINEERED IMMUNOCYTOKINES, FUSION POLYPEPTIDES, AND IL10 POLYPEPTIDES | SYNERKINE PHARMA B V (NL) | 2026-05-14 | — | — | US | disclosed |
| US-12584916-B2 | Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues | CISBIO BIOASSAYS (FR) | 2026-03-24 | — | — | US | disclosed |
| US-12522656-B2 | Anti-G-protein alpha antibody | CISBIO BIOASSAYS (FR) | 2026-01-13 | — | — | US | disclosed |
| US-5767278-A | ANTICARCINOGENIC AGENTS | GERON CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5760062-A | ANTICANCER AGENTS | GERON CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5703116-A | TREATING CANCER | GERON CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5656638-A | ANTICANCER, ANTITUMOR AGENTS | GERON CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | GNG2, GNAI3, GNAI2 | NT5E 257/4885TGM2 353/4885KRAS 72/4885 |
| US-20260132178-A1 | ENGINEERED IMMUNOCYTOKINES, FUSION POLYPEPTIDES, AND IL10 POLYPEPTIDES | IL4, IL2, IL2RA | NT5E 2302/4885TGM2 2812/4885KRAS 4427/4885 |
| US-12584916-B2 | Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues | GNAI1, GNAI3, GNB1 | NT5E 1604/4885TGM2 584/4885KRAS 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.